A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias.
Lionetti M et al. Oncotarget. 2015 Jul 20. [Epub ahead of print].
The natural compound forskolin synergizes with dexamethasone to induce cell death in myeloma cells via BIM.
Follin-Arbelet V et al. Sci Rep. 2015 Aug 26;5:13001. doi: 10.1038/srep13001.
Notch signaling deregulation in multiple myeloma: A rational molecular target.
Colombo M et al. Oncotarget. 2015 Aug 13. [Epub ahead of print].
Common genetic variants in 11q13.3 and 9q22.33 are associated with molecular subgroups of multiple myeloma.
Erickson SW et al. Leukemia. 2015 Aug 26. doi: 10.1038/leu.2015.238. [Epub ahead of print].
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.
Walker BA et al. J Clin Oncol. 2015 Aug 17. pii: JCO.2014.59.1503. [Epub ahead of print].
GDF15 promotes osteoclast differentiation, inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease.
Westhrin M et al. Haematologica. 2015 Aug 20. pii: haematol.2015.124511. [Epub ahead of print].
Multiple myeloma and bone marrow mesenchymal stem cells’ crosstalk: Effect on translation initiation.
Attar-Schneider O et al. Mol Carcinog. 2015 Aug 21. doi: 10.1002/mc.22378. [Epub ahead of print].
Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma.
Prabhala RH et al. Leukemia. 2015 Aug 21. doi: 10.1038/leu.2015.228. [Epub ahead of print].
Recent Advances in Computer-Assisted Structure-Based Identification and Design of Histone Deacetylases Inhibitors.
Krishna DS et al. Curr Top Med Chem. 2015 Aug 25. [Epub ahead of print].
CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance.
Carulli G et al. Acta Haematol. 2015 Aug 15;135(1):11-14. [Epub ahead of print].
Myeloma propagating cells, drug resistance and relapse.
Karadimitris A et al. Stem Cells. 2015 Aug 25. doi: 10.1002/stem.2199. [Epub ahead of print].
Chromosome Condensation 1-Like (Chc1L) Is a Novel Tumor Suppressor Involved in Development of Histiocyte-Rich Neoplasms.
Spillane DR et al. PLoS One. 2015 Aug 20;10(8):e0135755. doi: 10.1371/journal.pone.0135755. eCollection 2015.
The forkhead transcription factor FOXP1 represses human plasma cell differentiation.
van Keimpema M et al. Blood. 2015 Aug 19. pii: blood-2015-02-626176. [Epub ahead of print].
Multiple Myeloma: New Surface Antigens for the Characterization of Plasma Cells in the Era of Novel Agents.
Vittorio Emanuele M et al. Cytometry B Clin Cytom. 2015 Aug 19. doi: 10.1002/cyto.b.21279. [Epub ahead of print].
Blocking the ZZ domain of sequestosome 1/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo.
Teramachi J et al. Leukemia. 2015 Aug 19. doi: 10.1038/leu.2015.229. [Epub ahead of print].
Systemic modeling myeloma-osteoclast interactions under normoxic/hypoxic condition using a novel computational approach.
Ji Z et al. Sci Rep. 2015 Aug 18;5:13291. doi: 10.1038/srep13291.
Detection of chromosome 13 (13q14) deletion among Sudanese patients with multiple myeloma using a molecular genetics fluorescent in situ hybridization technique (FISH).
Dowd AA et al. Malays J Pathol. 2015 Aug;37(2):95-100.
Unabridged Analysis of Human Histone H3 by Differential Top-Down Mass Spectrometry Reveals Hypermethylated Proteoforms from MMSET/NSD2 Overexpression.
Zheng Y et al. Mol Cell Proteomics. 2015 Aug 13. pii: mcp.M115.053819. [Epub ahead of print].
Increased expression of metalloproteinase-2 and -9 (MMP-2, MMP-9), tissue inhibitor of metalloproteinase-1 and -2 (TIMP-1, TIMP-2), and EMMPRIN (CD147) in multiple myeloma.
Urbaniak-Kujda D et al. Hematology. 2015 Aug 13. [Epub ahead of print].
Sphingosine kinase-1 protects multiple myeloma from apoptosis driven by cancer specific inhibition of RTKs.
Tsukamoto S et al. Mol Cancer Ther. 2015 Aug 11. pii: molcanther.0185.2015. [Epub ahead of print].
Targeting executioner procaspase-3 with the procaspase activating compound B-PAC-1 induces apoptosis inmultiple myeloma cells.
Zaman S et al. Exp Hematol. 2015 Aug 6. pii: S0301-472X(15)00531-7. doi: 10.1016/j.exphem.2015.07.005. [Epub ahead of print].
Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.
Siegel MB et al. Oncotarget. 2015 Aug 7;6(22):18921-32.
Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma.
Koerber RM et al. Exp Hematol Oncol. 2015 Aug 5;4:21. doi: 10.1186/s40164-015-0016-z. eCollection 2015.
Targeting the miR-221-222/PUMA/BAK/BAX pathway abrogates dexamethasone resistance in multiple myeloma.
Zhao JJ et al. Cancer Res. 2015 Aug 6. pii: canres.0457.2015. [Epub ahead of print].
A unique aptamer-drug conjugate for targeted therapy of multiple myeloma.
Wen J et al. Leukemia. 2015 Aug 5. doi: 10.1038/leu.2015.216. [Epub ahead of print].
Ancient hot and cold genes and chemotherapy resistance emergence.
Wu A et al. Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):10467-72. doi: 10.1073/pnas.1512396112. Epub 2015 Aug 3.
VR23: a quinoline-sulfonyl hybrid proteasome inhibitor that selectively kills cancer via cyclin E-mediated centrosome amplification.
Pundir S et al. Cancer Res. 2015 Aug 3. pii: canres.3370.2014. [Epub ahead of print].
A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
Liu Y et al. FASEB J. 2015 Jul 31. pii: fj.15-274050. [Epub ahead of print].
Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim.
Nguyen M et al. BMC Cancer. 2015 Aug 1;15:568. doi: 10.1186/s12885-015-1582-5.
Affinity-Enhanced TCR-Engineered T Cells Induce Antimyeloma Responses.
[No authors listed] Cancer Discov. 2015 Jul 30. [Epub ahead of print].
Inhibiting MEK in MAPK pathway activated myeloma.
Heuck CJ et al. Leukemia. 2015 Jul 31. doi: 10.1038/leu.2015.208. [Epub ahead of print].
Effects of β-catenin on differentially expressed genes in multiple myeloma.
Chen H et al. J Huazhong Univ Sci Technolog Med Sci. 2015 Aug;35(4):546-52. doi: 10.1007/s11596-015-1468-4. Epub 2015 Jul 31.
Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma.
Di Martino MT et al. Oncotarget. 2015 Aug 7;6(22):19132-47.
Alantolactone induces G1 phase arrest and apoptosis of multiple myeloma cells and overcomes bortezomib resistance.
Yao Y et al. Apoptosis. 2015 Aug;20(8):1122-33. doi: 10.1007/s10495-015-1140-2.
FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells.
Suvannasankha A et al. Oncotarget. 2015 Aug 14;6(23):19647-19660.